Tzield Accepted for Priority FDA Review
There’s good news on the horizon for people at risk for a type 1 diabetes (T1D) diagnosis, especially parents of young children. Sanofi recently announced that its drug to delay…
There’s good news on the horizon for people at risk for a type 1 diabetes (T1D) diagnosis, especially parents of young children. Sanofi recently announced that its drug to delay…
Sanofi announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review its supplemental Biologics License Application (sBLA) for Tzield (teplizumab-mzwv) targeting young children with stage 2…
MedWatchUS FDA grants priority review for Sanofi’s type 1 diabetes drugFrance is seeking fast-track approval of diabetes drug Tzield in children aged over one..2 hours ago
Sanofi’s Tzield accepted for priority review in the US for young children with stage 2 type 1 diabetes If approved, Tzield would be the first disease-modifying therapy to delay the…
Jacob T. Wittman, PhD1; Dayna S. Alexander, DrPH1; Melissa Bing, MPH1; Robert Montierth, PharmD, MBA1; Hui Xie, PhD1; Stephen R. Benoit, MD, MPH1; Kai McKeever Bullard, MPH, PhD1 (View author…